Brind.
  1. Aurinia's LUPKYNIS received FDA approval on July 31, 2025.

Teva is challenging Aurinia's patents regarding LUPKYNIS, while Aurinia defends against generic applications from Sandoz.

2 reports, 1 independent Updated Aug 28
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Teva is challenging Aurinia's patents regarding LUPKYNIS, while Aurinia defends against generic applications from Sandoz.

Who's involved

What this event is mainly about
Teva Pharmaceutical Industries Ltd.Sandoz

Keep exploring

Part of

Aurinia's LUPKYNIS received FDA approval on July 31, 2025. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story